Innovative Molecular Analysis Technologies
The Innovative Molecular Analysis Technologies (IMAT) Program is aimed at the inception, development, integration, and application of novel and emerging technologies in support of cancer research, treatment, diagnosis, and prevention. The IMAT Program utilizes different funding mechanisms to accomplish these goals, including the SBIR grant mechanisms. For more information about the IMAT Program, please visit: innovation.cancer.gov.
The Innovative Emerging Molecular Analysis Technologies grant will provide funding to small businesses conducting research towards the commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization.
NCI-SBIR plans to support five projects awarded in 2011 and companies with an emphasis on molecular analysis technologies to improve cancer prevention, detection and diagnosis, surveillance, epidemiological research, and basic cancer research are encouraged to apply. Applications must demonstrate rationale pointing to the commercial potential of the technology to be developed. Please note, prior participation in the IMAT Program is not required for this funding opportunity.
To learn more about the NCI Innovative Molecular Analysis Technologies program, visit: innovation.cancer.gov.
The deadline for receipt of the Innovative Emerging Molecular Analysis Technologies has passed.
Click here to view all past IMAT Program FOAs.